Isofol Medical AB

Isofol Medical AB

0.10
EUR
0.00
(0.00%)
-0.02EPS
20.96MMarket Cap
Feb 12Next Earn

Total Valuation

EUR

As of June 30, 2026, Isofol Medical AB carries a market capitalization of 20.96M, placing it among publicly traded companies globally. Its enterprise value stands at 10.59M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Market Cap20.96M
Enterprise Value10.59M

Important Dates

Isofol Medical AB's next confirmed earnings release is scheduled for February 12, 2027.

Earnings Date2/12/2027

Share Statistics

As of June 30, 2026, Isofol Medical AB has 320.49M shares outstanding.

Shares Outstanding320.49M

Valuation Ratios

These figures are as of June 30, 2026.

PB Ratio2.44
P/TBV Ratio2.44
P/FCF Ratio-3.85
P/OCF Ratio-3.85

Financial Position

As of June 30, 2026, Isofol Medical AB maintains a current ratio of 5.17, meaning it holds 5.2x the short-term assets needed to cover near-term liabilities.

Current Ratio5.17
Quick Ratio5.01
Interest Coverage-29,423.00

Financial Efficiency

Over the twelve months ended June 30, 2026, Isofol Medical AB posted a negative return on equity (ROE) of -78.31, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -60.35, reflecting losses generated across the asset base. The company generates approximately - - in revenue per employee across its workforce of 5.75, a quick read on workforce productivity versus industry peers.

Return on Equity (ROE)-78.31
Return on Assets (ROA)-60.35
Employee Count5.75

Stock Price Statistics

EUR

As of the close on November 17, 2026, Isofol Medical AB's stock has gained approximately 52.88% over the past 52 weeks. The 50-day moving average sits at 0.09, while the 200-day moving average is 0.07.

52-Week Price Change52.88%
50-Day Moving Average0.09
200-Day Moving Average0.07

Income Statement

EUR

Over the twelve months ended June 30, 2026, Isofol Medical AB generated - - in revenue and converted that into -5.11M in net income, yielding earnings per share of -0.02. EBITDA reached -5.31M, while operating income came in at -5.31M.

Operating Income-5.31M
Pretax Income-5.11M
Net Income-5.11M
EBITDA-5.31M
EBIT-5.31M
Earnings Per Share (EPS)-0.02

Balance Sheet

EUR

These figures are as of June 30, 2026. Total book value stands at 8.58M, with working capital of 8.63M providing operational flexibility.

Cash & Cash Equivalents10.37M
Net Debt-2.65M
Equity (Book Value)8.58M
Book Value Per Share0.03
Working Capital8.63M

Cash Flow

EUR

Isofol Medical AB produced -4.75M in operating cash flow over the twelve months ended June 30, 2026.

Operating Cash Flow-4.75M
Free Cash Flow-4.75M
FCF Per Share-0.02

Dividends & Yields

These figures cover the twelve months ended June 30, 2026. Free cash flow yield is negative at -25.95: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -43.92, meaning Isofol Medical AB raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Shareholder Yield-43.92
FCF Yield-25.95

Stock Splits

Isofol Medical AB's most recent stock split took place on June 13, 2025.

Last Split Date6/13/2025

Scores

As of June 30, 2026, Isofol Medical AB has an Altman Z-Score of -9.28, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.

Altman Z-Score-9.28